Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study — Brett Marinelli (2022) | RDL Network
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study
Article 2022 en
Authors
BM
Brett Marinelli
EK
Edward Kim
AD
Antonio D’Alessio
Abstract
1 min read
TACE can be safely integrated with programmed cell death 1 blockade and may lead to a significant delay in tumor progression and disease downstaging in selected patients.
Anthony B. El-Khoueiry, Josep M. Llovet, Arndt Vogel, David C. Madoff, Richard S. Finn, Sadahisa Ogasawara, Zhenggang Ren, Kalgi Mody, Jerry J Li, Abby B. Siegel, Leonid Dubrovsky, Masatoshi Kudo
Discussion(0)
No comments yet. Be the first to comment.